Enable AccessibilityEnable Accessibility

Takeda Supports Crohn’s and Colitis Canada PACE Network with $500,000 contribution

May 10, 2016
Collaboration aims to improve quality of life for Canadians with Crohn’s and colitis

OAKVILLE, Ontario – May 11, 2016 – Takeda Canada Inc. announced today its support for the Promoting Access and Care through Centres of Excellence (PACE) network and will be contributing $125,000 per year over four years, for a total of $500,000.

The Crohn’s and Colitis Canada PACE network is a unique charity-pharmaceutical industry collaboration that aims to improve quality of life for patients living with Crohn’s disease and ulcerative colitis – the two main forms of inflammatory bowel disease (IBD) – through the establishment of a national network of IBD Centres of Excellence.

“PACE brings together world-class patient care and research centres to advance the standard of care for Canadians living with Crohn’s disease and ulcerative colitis,” said Mina Mawani, President and CEO of Crohn’s and Colitis Canada. “Support from Takeda Canada and other industry partners is essential to the success of initiatives like PACE for the benefit of patients living with chronic diseases.”
Today’s announcement coincides with launch events at several of the IBD centres of excellence participating in the PACE network: Mount Sinai Hospital, McMaster University, and McGill University including research leads in each centre, pharmaceutical industry representatives, patients, and government dignitaries.

“Takeda Canada places great importance on its work in gastroenterology and IBD in particular. We recognize the challenges that people living with IBD face on a daily basis which is why we strive to help meet the needs of Canadian patients in as many ways as we can,” said Chatrick Paul, General Manager, Takeda Canada Inc. “It was clear to us that we needed to be involved in PACE because it identified crucial gaps in patient care and proposed very concrete plans to fill them. We are very pleased to support this network and look forward to seeing the results.”
Takeda Canada is a strong supporter of Crohn’s disease and ulcerative colitis research in Canada. The company’s support of the PACE network is the second major investment this year. Takeda recently invested $2.1 million in the Strategy for Patient-Oriented Research (SPOR) patient-centred gastrointestinal research initiative, IMAGINE, led by McMaster University.

About PACE

The Promoting Access and Care through Centres of Excellence (PACE) network will enable world-renowned Canadian leaders in Crohn’s disease and ulcerative colitis to share resources and work together to improve the standard of care across the country. PACE, facilitated by Crohn’s and Colitis Canada, brings together leading IBD centres to collectively advance best practices, standardize the delivery of care and reduce chronic steroid use.

About Takeda Canada

Takeda Canada, located in Oakville, Ontario, is the Canadian sales and marketing organization of Takeda Pharmaceutical Company Limited, Osaka, Japan. The company has a commercial presence covering more than 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China. Areas of focus include metabolic, oncology, central nervous system, general medicine, and vaccines.

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Through strategic acquisitions, Takeda has been transforming itself, broadening its therapeutic expertise and geographic outreach.

Additional information about Takeda Canada is available through its website: www.takedacanada.com.


Natacha Raphael
[email protected]